TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. (2021) Grivas P, Tagawa ST, Bellmunt J, De Santis M, Duran I, Goebell P, Necchi A, et al. Conference contribution Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer (2020) Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, Zlobec I, et al. Journal article Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts (2020) Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, et al. Journal article Anti–B-cell maturation antigen bite molecule AMG 420 induces responses in multiple myeloma (2020) Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, Kroenke J, et al. Journal article Predictive value of fibroblast growth factor receptor (FGFR) alterations on anti-PD-(L)1 treatment outcomes in patients (Pts) with advanced urothelial cancer (UC): Pooled analysis of real-world data (2020) Kim WY, Rose T, Roghmann F, Eckstein M, Jarczyk J, Zengerling F, Sikic D, et al. Conference contribution Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy (2020) Gupta S, Sonpavde G, Weight C, McGregor BA, Gupta S, Maughan BL, Wei X, et al. Conference contribution Association of KRT20 and KRT5 with response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer (2020) Roghmann F, Reike M, Wirtz R, Kriegmair M, Erben P, Tully K, Weyerer V, et al. Conference contribution Smoking status and PD-L1 mRNA-expression as a predictor of response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer (2020) Reike M, Juette H, Wirtz R, Erben P, Tully K, Eckstein M, Weyerer V, et al. Conference contribution Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12 (2019) Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, et al. Journal article Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node (2019) Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Sunderkötter C, Kaatz M, et al. Journal article